US EditionNLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Prescription Omega-3 Fatty Acids Examined for Cardiovascular Risk Management at NLA 2025 Conference
At the NLA 2025 conference, Frank Qian, MD, MPH, presen […] The post Prescription Omega-3 Fatty Acids Examined for Cardiovascular Risk Management at NLA 2025 Conference first appeared on GeneOnline News. The post Prescription Omega-3 Fatty Acids Examined for Cardiovascular Risk Management at NLA 2025 Conference appeared first on GeneOnline News.
NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk
Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
